Sanofi (SNY)
(Delayed Data from NSDQ)
$53.10 USD
+1.90 (3.71%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $53.09 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.10 USD
+1.90 (3.71%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $53.09 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
Why Biotech ETFs are Surging to New Highs
by Neena Mishra
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Biotech ETFs Hit New Highs on Deal Activities
by Sweta Killa
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research
by Zacks Equity Research
Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.
Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms
by Kinjel Shah
Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.
Week Begins with Biotech Mergers
by Zacks Equity Research
Week Begins with Biotech Mergers
Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More
by Mark Vickery
Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).
Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio
by Zacks Equity Research
Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.
Regeneron Reports Positive Data on Rare Blood Disorder Drug
by Zacks Equity Research
Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.
Alnylam Gets Second Product Approval Amid Stiff Competition
by Zacks Equity Research
Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
Esperion's Promising Drugs Under Review, Funds a Concern
by Zacks Equity Research
Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize the launch.
Novartis (NVS) to Acquire The Medicines Company for $9.7B
by Zacks Equity Research
Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.
Amarin's Shares Down on Underperform Rating by Oppenheimer
by Zacks Equity Research
Amarin's (AMRN) shares decline as the independent advisory firm, Oppenheimer, initiates coverage with an Underperform rating on the back of concerns related to its marketed drug, Vascepa.
Protalix Finalizes Accelerated Approval Pathway for PRX-102
by Zacks Equity Research
Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.
The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody's
Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion
by Zacks Equity Research
Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.
Top Stock Reports for Chevron, HSBC & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), HSBC Holdings (HSBC) and Sanofi (SNY).
Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study
by Zacks Equity Research
GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.
Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus
by Zacks Equity Research
Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products
by Kinjel Shah
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales
by Zacks Equity Research
Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.
Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength
by Zacks Equity Research
Regeneron (REGN) beats on Q3 earnings and sales on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.
Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.
Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alnylam (ALNY) incurs narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales
by Zacks Equity Research
Sanofi (SNY) reports mixed third-quarter results with strong Specialty Care sales but soft Vaccines & Consumer Healthcare sales.